InVivo Therapeutics Holdings Corp. Terminates Thomas Ulich as Chief Scientific Officer, Effective on August 30, 2017
August 28, 2017 at 04:42 pm EDT
On August 28, 2017, a committee of the board of directors of InVivo Therapeutics Holdings Corp. approved a strategic restructuring of the company that will refocus the company's efforts on re-opening enrollment for and completing the company's INSPIRE clinical trial. In connection with the restructuring, on August 28, 2017, the company notified Thomas Ulich, M.D., the company's chief scientific officer, that his employment will be terminated effective August 30, 2017.